AdvanDx

AdvanDx is a biotechnology company based in Woburn, Massachusetts, focused on developing and marketing rapid molecular diagnostic tests for identifying pathogens that cause critical infections, particularly bloodstream infections in hospitalized patients. Founded in 2002, the company utilizes proprietary technologies like Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) and EVIGENE for fast and specific analysis of bacterial and yeast species from positive blood cultures. The core product line includes FDA-approved and CE-marked rapid molecular tests, such as the QuickFISH™ assays, which deliver pathogen identification results in approximately 20 minutes to three hours. This rapid identification aids clinical microbiology laboratories in providing timely and accurate information, supporting healthcare providers in making informed antibiotic therapy decisions. AdvanDx’s products are primarily intended for in vitro diagnostic use in the U.S., Canada, and Europe, and the company serves clinical microbiology laboratories, hospitals, and healthcare providers focused on managing infectious diseases. In 2015, AdvanDx was acquired by OpGen, Inc., enhancing its capabilities in rapid testing solutions for infectious disease management.

• Employees 12
• Founded 2002
• Annual Revenue $5000000
• Total Funding $44700000